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Cardiovascular diseases can be considered the most important cause of death in
diabetic population and diabetes can in turn increase the risk of cardiovascular events.
Inflammation process is currently recognized as responsible for the development
and maintenance of diverse chronic diseases, including diabetes and atherosclerosis.
Considering that adipose tissue is an important source of adipokines, which may present
anti and proinflammatory effects, the aim of this review is to explore the role of the
main adipokines in the pathophysiology of diabetes and atherosclerosis, highlighting the
therapeutic options that could arise from the manipulation of these signaling pathways
both in humans and in translational models.
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INTRODUCTION
Diabetes mellitus (DM) is characterized by insufficient production of insulin (type 1) or, more
commonly, inefficient insulin signaling pathways (type 2), a state known as insulin resistance (IR)
(International Diabetes Federation, 2013; American Diabetes Association, 2014). Cardiovascular
diseases (CVD) are the most important cause of death in the diabetic population (Skyler et al.,
2009; American Diabetes Association, 2014). Obesity, a global health problem, is characterized by
overproduction of inflammatory adipokines by adipose tissue and this may be the link between
obesity, CVD and diabetes (Ohman et al., 2008).
Adipokines can be defined as a group of over 600 bioactive molecules produced by adipose
tissue that acts as paracrine and endocrine hormones (Blüher, 2014). These molecules are
important in the regulation of diverse processes including appetite and satiety, fat distribution,
inflammation, blood pressure, hemostasis and endothelial function. They act in different organs
including adipose tissue itself, brain, liver, muscle and vessels (Blüher, 2009, 2014; Lehr et al.,
2012; Van de Voorde et al., 2013). These adipokines include mainly adiponectin, leptin, tumor
necrosis factor alpha (TNFα), osteoprotegerin, interleukin 6 (IL-6), resistin, interleukin 1 (IL-
1), apelin, visfatin, monocyte chemotactic protein-1 (MCP-1), plasminogen activator inhibitor-1
(PAI-1), retinol binding protein 4 (RBP4) and others (Van de Voorde et al., 2013; Blüher, 2014;
Fisman and Tenenbaum, 2014). The pattern of secretion of adipokines can reflect adipose tissue
function and this pattern is important to establish the individual risk to develop metabolic and
cardiovascular comorbidities of obesity (Blüher, 2009, 2014). When adipose tissue inflammation
and dysfunction are established, adipokine secretion is significantly changed toward a diabetogenic,
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FIGURE 1 | Over nutrition, metabolic syndrome and/or genetic predisposition may contribute to obesity development and modulate adipokine profile
resulting in a low-grade inflammatory state which is associated with increased risk of insulin resistance and atherosclerosis.
proinflammatory and atherogenic pattern (Blüher, 2009, 2014),
as represented in Figure 1. The nature of obesity-induced
inflammation is different from other inflammatory situations
such as infections or autoimmune diseases. Considering that
obesity is a chronic condition, it produces a low-grade activation
of innate immune system that affects homeostasis over time
(Lumeng and Saltiel, 2011). It is important to highlight that
adipose tissue macrophages (ATM) can also be considered as
important sources of proinflammatory cytokines (Xu et al., 2015).
Although diabetes and other cardiovascular complications
such as atherosclerosis have increasing importance in modern
societies, the high mortality due to these diseases reveals that
there are insufficient treatment options. Considering that, in the
present review we provide an overview on the involvement of
the main pro and anti-inflammatory adipokines in diabetes and
atherosclerosis and discuss the therapeutic alternatives that could
arise from the manipulation of these signaling pathways.
ADIPOKINES AND DIABETES
Insulin resistance (IR) is known to be an important factor
underlying the pathogenesis of type 2 diabetes and it usually
precedes the onset of this disease (Xu et al., 2015). It occurs in
several tissues including liver, muscle and adipose tissue (Lee and
Lee, 2014). Cytokines released by adipose tissue are involved in
initiating and promoting a proinflammatory status, contributing
to IR (Timar et al., 2014). Moreover, these molecules are involved
in regulation of insulin sensitivity and secretion (Blüher, 2014).
Thus, the impaired adipokine production observed in obesity
contributes to diabetes pathogenesis. In metabolic syndrome
(MS), adipocytes secrete factors that reduce insulin-mediated
glucose uptake (including free fatty acids and proinflammatory
cytokines) (Havel, 2002; Timar et al., 2014). The interaction if
the main adipokines discussed in the present work to promote
insulin resistance are illustrated in Figure 2.
Modulation of Insulin Sensitivity by
Adiponectin
Adiponectin links visceral adiposity, IR, and atherosclerosis
(Swarbrick andHavel, 2008). Unlike other adipokines, circulating
concentration of adiponectin is inversely proportional to
adiposity and low adiponectin levels predict the development
of DM and CVD (Arita et al., 1999; Kadowaki et al., 2006).
Moreover, strategies known to help delay or prevent DM and
CVD like low-calorie, high-unsaturated fat diet and/or exercise
are associated with increased circulating adiponectin levels
(Esposito et al., 2003; Lim et al., 2014). Thus, adiponectin
may contribute to the prevention of these diseases (Lim et al.,
2014), although its use as a marker of cardiovascular risk is still
controversial, as further discussed. Adiponectin production is
primarily determined by adipocyte size and insulin sensitivity. It
was observed that larger and insulin-resistant adipocytes produce
less adiponectin (Bahceci et al., 2007; Swarbrick andHavel, 2008).
Other cells and tissues can also secrete adiponectin, including
cardiomyocytes (Waki et al., 2005; Huang et al., 2009; Caselli
et al., 2014).
Independent groups revealed the insulin-sensitizing effect of
adiponectin (Berg et al., 2001; Yamauchi et al., 2001; Kadowaki
et al., 2006; Wascher et al., 2011). These researchers took the
first steps to unravel the mechanisms involving adipokines
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FIGURE 2 | Increase in adipose tissue mass is related to increase in MCP-1, which favors macrophages migration to adipose tissue and the
production of other adipokines such as IL-6 and TNFα. On the other hand, obese adipose tissue produces less adiponectin. Taken together, these features
reduce glucose uptake in muscle cells and favors glycogenolisis and gluconeogenesis in liver, which contribute to insulin resistance and diabetes.
and insulin resistance. Yamauchi et al. observed that the
replenishment of adiponectin significantly ameliorates high-fat
diet-induced insulin resistance and hypertriglyceridemia. They
proposed that adiponectin is an insulin-sensitizing adipokine
(Yamauchi et al., 2001). It has been described that an acute
increase in the concentration of circulating adiponectin triggers
a transient decrease in basal glucose level by inhibiting both
the expression of hepatic gluconeogenic enzymes and the rate
of endogenous glucose production in both wild-type and type
2 diabetic mice, suggesting that adiponectin sensitizes the body
to insulin (Berg et al., 2001; Wascher et al., 2011). It was
reported that a proteolytic cleavage product of adiponectin,
which structurally resembles globular adiponectin, increases
fatty-acid oxidation in muscle, decreases plasma glucose and
causes weight loss in mice (Fruebis et al., 2001).
Adiponectin Receptors
Adiponectin interacts with two different transmembrane
receptors: AdipoR1 (expressed ubiquitously and at a high level
in skeletal muscle) and AdipoR2 (expressed predominantly in
the liver) (Yamauchi et al., 2003a; Scheid and Sweeney, 2014).
It was detected that the deletion of both AdipoR1 and AdipoR2
in mice led to increased lipid accumulation in various tissues,
IR and glucose intolerance. AdipoR1 deletion results in lack of
adiponectin-stimulated adenosine monophosphate-activated
protein kinase (AMPK) activation (Yamauchi et al., 2007).
When AdipoR2 is deleted, the principal signaling defect occurs
in peroxisome proliferator-activated receptor alpha (PPARα)
signaling (Yamauchi et al., 2007) AdipoR1−/− mice exhibited
decreased glucose tolerance and defective AMPK activation
(Scheid and Sweeney, 2014). On the other hand, cultured
myotubes from obese diabetic participants showed increased
levels of AdipoR1 relative to lean controls (Holmes et al., 2011).
Jang and colleagues reported that AdipoR2 levels are significantly
lower in DM participants than in lean controls. These findings
suggest that circulating levels of adiponectin and expression of
AdipoR genes play an important role in the regulation of skeletal
muscle insulin action (Chen et al., 2005; Jang et al., 2008; Holmes
et al., 2011), although the exact effect of adiponectin in type 1
or type 2 receptors in different CVD is still under investigation.
Okada-Iwabu and collaborators observed that orally active
AdipoR agonists (AdipoRON) presented similar effects to
adiponectin via AdipoR1 and 2 in both liver and skeletal muscle
of diabetic mouse model, suggesting that adiponectin receptors
could be a promising therapeutic target for the oral treatment of
DM (Okada-Iwabu et al., 2013). Adiponectin receptors are also
expressed in pancreatic β-cells and their expression is increased
by exposure to free fatty acids, suggesting that adiponectin and
its receptors are also involved in insulin secretion (Lim et al.,
2014).
It is already established that AdipoR1 activates AMPK,
promoting glucose uptake in muscle cells via translocation
of GLUT4 transporters to cellular membrane (Fisman and
Tenenbaum, 2014). Simultaneously, it blocks gluconeogenesis by
inhibiting the hepatic enzyme phosphoenolpyruvate carboxylase,
inhibits the synthesis of fatty acids and stimulates their oxidation
(Kadowaki et al., 2006; Scheid and Sweeney, 2014). Moreover,
adiponectin also increases fatty-acid combustion and energy
consumption via activation of AdipoR2 through PPARα and
PPARγ activation, which leads to glucose uptake and decreased
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triglyceride content in the liver and skeletal muscle, contributing
to in vivo insulin sensitivity (Kumada et al., 2004; Kadowaki
et al., 2006; Lim et al., 2014). Interestingly, AMPK can directly
increase insulin sensitivity by stimulating the phosphorylation
of peroxisome proliferator-activated receptor-γ co-activator 1 α
(PGC-1α), a transcription co-activator that plays a critical role in
the biosynthesis of mitochondria and oxidative phosphorylation.
This reveals a cross-talk between the two different adiponectin
receptors (Jäger et al., 2007; Scheid and Sweeney, 2014).
Finally, adiponectin also enhances insulin sensitivity indirectly by
increasing hepatic insulin receptor substrate 1 (IRS-1) expression
via a macrophage-derived IL-6-dependent pathway. Thus, these
multiple actions confer to adiponectin a key role in ensuring
an effective protection against the development of IR (Awazawa
et al., 2011; Fisman and Tenenbaum, 2014). In summary,
adiponectin has insulin-sensitizing and cardiovascular-protective
effects. These properties may help explain the inverse association
between circulating adiponectin level and CVD, DM and obesity.
TNFα-induced Insulin Resistance
The mechanistic link between obesity, DM, and adipose tissue
inflammation was first proposed based on the finding that the
level of the proinflammatory adipokine TNFα was increased
in adipose tissue of obese rodents and humans and that its
blockage led to improvement in insulin sensitivity (Hotamisligil
et al., 1993). Subsequently, macrophages were found to infiltrate
into adipose tissue of obese mice and humans and nearly 40–
50% of total cells are F4/80-expressing macrophages in mice.
These cells were also the major source of TNFα in adipose
tissue (Weisberg et al., 2003; Cildir et al., 2013). The interaction
between TNFα and its receptors, TNFR1 and TNFR2, mediates
apoptosis, IR, lipolysis, inhibition of insulin-stimulated glucose
transport and inhibition of insulin receptor autophosphorylation
(Blüher, 2009; Cildir et al., 2013; Palomer et al., 2013). In
adipocytes, TNFα reduces the secretion of adiponectin, induces
IR and favors atherogenic dyslipidemia due to the reduction in
GLUT4 expression, reduction in lipoprotein lipase (LPL) activity
and increasing in expression of hormone-sensitive lipase (Cildir
et al., 2013). TNFα impairs insulin signaling in adipocytes and
hepatocytes through activation of stress-related protein kinases,
as JNK-1, and activation of the IKKB/NF-κB pathway (Hirosumi
et al., 2002; Arkan et al., 2005; Tarantino and Caputi, 2011)
In addition, TNFα stimulates inhibitory phosphorylation of the
serine residues of IRS-1, which is recognized as the major
pathway in IR, corroborating the link between inflammation,
obesity and IR (Wellen and Hotamisligil, 2005).
TNFα antagonism is efficient to treat patients with chronic
inflammatory conditions such as rheumatoid arthritis. However,
studies using anti-TNF therapies did not show significant
improvement in insulin sensitivity. In obese Zucker rats, anti-
TNF treatment had no effect on insulin sensitivity or lipid profile
(López-Soriano et al., 1997; Cildir et al., 2013). Controversially, in
some rodent studies, administration of TNFα antibodies resulted
in inhibited inflammatory activity, improved fatty liver disease,
protection against diet-induced obesity and IR (Li et al., 2003;
Liang et al., 2008; Blüher, 2009). Unfortunately, the promising
results from some animal studies using anti-TNF treatment in
metabolic diseases were not successful clinically (Blüher, 2009).
In a recent study, chronic TNFα neutralization by infliximab led
to improvement in inflammatory status but did not ameliorate IR
nor endothelial function in insulin-resistant volunteers (Wascher
et al., 2011). Therefore, the effect of TNFα neutralization on
insulin sensitivity in patients with DM needs to be further
evaluated to open the perspective of new pharmacological targets.
Interleukin-6 and Insulin Resistance
Interleukin-6 (IL-6) can be considered an adipokine since it is
released by adipocytes from obese individuals, which occurs in
a size-dependent manner (i.e., larger adipocytes release greater
amounts of IL-6) and links obesity to a state of low-grade
inflammation (Skurk et al., 2007; Schuett et al., 2009). The
IL-6 family includes a range of diverse molecules such as IL-
6 itself, IL-11, IL-27, IL-31, and others (Schuett et al., 2009;
Scheller et al., 2011). These molecules have a common feature
of containing two signal transducing receptor subunits, which
one of them is glycoprotein 130 (gp130) (Schuett et al., 2009;
Rose-John et al., 2015). Interestingly, only a few defined cell types
(e.g., hepatocytes, monocytes, neutrophils and inactive T- and B-
lymphocytes) express the specific IL-6 receptor (IL-6R) and can,
therefore, respond to IL-6 classic signaling pathways (Schuett
et al., 2009). However, a soluble form of IL-6R (sIL-6R) can be
released due to shedding by A disintegrin and metalloprotease
17 (ADAM17). Interleukin-6 can bind to sIL-6R and activate
gp130 in cells which do not former express IL-6R, a process
known as trans-signaling (Matthews et al., 2003; Schuett et al.,
2009; Scheller et al., 2011). This explains the wide range of
effects elicited by this adipokine in different cell types. The exact
metabolic role of IL-6 is still controversial because it has multiple
functions, including tissue-specific effects on glucose metabolism
and insulin signaling (Sabio and Davis, 2010). It appears to
present dual functions, depending on the target tissue (liver or
muscle), the duration of stimulus (acute vs. chronic) or the source
of the cytokine (adipose tissue or skeletal muscle) (Schuett et al.,
2009; Piya et al., 2013).
Chronically-elevated IL-6 has been described to be related to
metabolic disorders such as obesity and IR (Franckhauser et al.,
2008; Schuett et al., 2009). Circulating levels of IL-6 have been
reported to be positively associated with MS, IR and diabetes
(Ferreira-Hermosillo et al., 2015; Sindhu et al., 2015). Also,
IL-6 mediates, at least in part, hepatic insulin resistance due
to impairment of insulin receptor and IRS-1 phosphorylation
(Sabio and Davis, 2010; Piya et al., 2013). It appears that the
effect of IL-6 in hepatic control of insulin sensitivity and glucose
tolerance is mediated by IL-6 classic rather than trans-signaling
pathway (Scheller et al., 2011). This idea is reinforced by the
fact that liver expresses IL-6R and that a long-term IL-6 trans-
signaling inhibition in mice revealed no unfavorable metabolic
effects (Schuett et al., 2009). Chronically-elevated IL-6 levels also
lead to impaired insulin-mediated glucose uptake by muscle cells
(Hassan et al., 2014). On the other hand, during exercise, acutely
elevated IL-6 produced by skeletal muscle increases glucose
uptake and AMPK-mediated fatty acid oxidation in these cells
(Schuett et al., 2009; Piya et al., 2013). Considering the dual
roles played by IL-6 on insulin sensitivity in diverse tissues and
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that these effects depend on different times of exposition and
signaling pathways, further studies are necessary to ensure the
safety of blocking IL-6 pathways as a pharmacological target to
treat diabetes.
MCP-1 and Insulin Resistance
Monocyte chemoattractant protein 1 (MCP-1) (also referred
as chemokine C-C motif ligand 2, CCL2) is involved in
leucocyte recruitment to inflammation sites. The effects of
MCP-1 in recruiting monocytes, T lymphocytes and natural
killer cells are dependent of the C-C motif chemokine receptor
(CCR2), since the use of a specific antagonist for this receptor
attenuates obesity-induced macrophage accumulation (Charo
and Taubman, 2004; Weisberg et al., 2006; Gonzalez-Quesada
and Frangogiannis, 2009). The interaction of MCP-1 with its
receptor, CCR2, is considered pivotal for the recruitment of
adipose tissue macrophages (ATMs) and the development of
obesity-induced insulin resistance, although ATM recruitment
can occur independently fromMCP-1/CCR2 signaling (Xu et al.,
2015). Adipocytes are an important source of MCP-1 and it
causes adipose tissue inflammation even in the absence of
macrophages (Sindhu et al., 2015). Adipose-derived MCP-1 is
critical in exacerbating insulin resistance in adipose tissue of
obese individuals (Uchida et al., 2012).
Interestingly, although chronic stress leads to atrophy of
adipose tissue with a reduction in cell size, it also induces a low-
grade inflammation status similar to obesity-related phenotype.
In this model, MCP-1 is involved in the establishment of IR and
a prothrombotic state (Uchida et al., 2012). Mice deficient in
MCP-1 or the CCR2 are protected against high fat diet-induced
IR (Weisberg et al., 2006). Although it was demonstrated that
MCP-1/CCR2 signaling is important for obesity-induced insulin
resistance and that the use of a CCR2 antagonist can ameliorate
this condition without affecting macrophage infiltration into
adipose tissue, it is difficult to state if IR is induced by MCP-
1 per se or if it depends on recruited macrophages that release
other cytokines (Kanda et al., 2006; Panee, 2012). Monocytes
recruited into adipose tissue by CCR2 activation also secrete
TNFα, IL-6 and MCP-1, which enhances the amplification
cascade and favors continuous adipose tissue inflammation
and IR through autocrine and paracrine interactions between
monocytes and adipocytes (Uchida et al., 2012). Nevertheless, it is
clear that MCP-1 links obesity to IR and macrophage infiltration
into adipose tissue (Kanda et al., 2006). Importantly, MCP-1
is involved in diabetic nephropathy. Under stimulation of a
high glucose concentration, advanced glycation end-products,
oxidatively modified lipoproteins and angiotensin II, MCP-1 is
expressed inmesangial cells, leading to glomerulosclerosis (Yadav
et al., 2010).
Leptin and Insulin Resistance
The implications of leptin in cardiovascular diseases has been
studied since its first description in the classical paper by Zhang
et al. (1994). Leptin is an adipose tissue-specific adipokine,
known as a key molecule that regulates appetite, energy
expenditure, behavior and glucose metabolism (Amitani et al.,
2013; Adya et al., 2015). It crosses blood-brain barrier and, in
hypothalamus, it acts in specific receptors to decrease appetite
and increase energy expenditure (Koh et al., 2012). Also, it
inhibits neuropeptide Y neurons (Elmquist et al., 1999). Leptin
plasma concentration increases in proportion to body fat mass
(Amitani et al., 2013). This adipokine acts on target cells through
transmembrane receptors, which exist in 6 different isoforms
(from Ob-Ra to Ob-Rf) (Koh et al., 2008; Adya et al., 2015). In
obesity, despite increased leptin levels, a dysregulation of energy
balance is observed, suggesting that obese people are resistant
to leptin (Seufert et al., 2004; Koh et al., 2008). According to
the concept of selective leptin resistance introduced by Mark
and colleagues in 2002, only the anorectic effect of leptin is
imbalanced, whereas other activities are maintained (Mark et al.,
2002; Koh et al., 2012). It is important to highlight that exogenous
leptin is efficient in promoting weight loss in obese humans and
mice genetic deficient in leptin but not in diet-induced obesity
(Blüher, 2014).
Leptin exerts an important role in regulation of glucose
homeostasis, independent of its actions on food intake or body
weight (Jung and Choi, 2014). Pancreatic β cells express leptin
receptors and leptin inhibits insulin biosynthesis and secretion
(Figure 3). There is a feedback loop where insulin stimulates
leptin secretion from adipose tissue (Amitani et al., 2013) and
leptin is decreased in low insulin states (Ahima and Flier,
2000). Several pathways are involved in leptin-induced inhibition
of insulin secretion: suppression of preproinsulin mRNA,
inhibition of GLP-1-induced insulin production, impairment
of glucose transport via GLUT 2, regulation of ATP-sensitive
potassium channels, inhibition of cAMP/PKA pathway, which
regulates calcium channels and exocytosis (Seufert et al., 2004;
Marroquí et al., 2012; Amitani et al., 2013). In skeletal muscle,
leptin can impair GLUT 4 translocation, which contributes to
insulin resistance (Figure 3) (Thorp and Schlaich, 2015). It was
demonstrated that insulin resistance is associated with elevated
plasma leptin levels (Segal et al., 1996). Thus, hyperleptinemia
can be considering another critical link between obesity and
insulin resistance. Given that leptin levels are increased in obesity
and that, due to selective leptin resistance, its proinflammatory
and insulin desensitizing effects are maintained, body weight
reduction is important in diabetic patients as a strategy to
preserve insulin efficacy.
ADIPOKINES AND ATHEROSCLEROSIS
Atherosclerosis can be defined as a chronic and progressive
disease characterized by an inflammatory response of arterial
wall to injuries promoted by risk factors such as dyslipidemia,
diabetes, hypertension and others (Ross, 1999). The concept
that atherosclerosis is an inflammatory disease is not new, since
the inflammatory nature of atherosclerotic plaque was already
described by Virchow in 1858 (Virchow, 1858, 1989). Although
hypercholesterolemia figures among the most important risk
factors for atherogenesis, nowadays it is well established that
atherosclerosis is not only the accumulation of fat in arterial
walls but is also a complex process involving both innate
and adaptive immune processes (Ross, 1999; Hansson et al.,
2002). In brief, atherogenic process initiates in sites where
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FIGURE 3 | In obesity, despite increased levels of leptin, central actions of this adipokine that control appetite, body weight, and energy expenditure
are impaired (a phenomena known as leptin resistance, represented in the figure by the crossed red arrow from adipose tissue to the brain and black
arrows). Otherwise, peripheral actions of leptin to reduce insulin secretion in pancreas and its signaling pathways is muscle (represented in the figure by plain arrows
from adipose tissue to pancreas and muscle) culminates in insulin resistance, hyperglycemia and diabetes.
endothelium is submitted to shear stress (i.e., aortic root, aortic
arch, superior mesenteric artery, and renal arteries). In these
sites, endothelial dysfunction is observed and the permeability
of the intimal layer is altered, favoring the migration of low
density lipoprotein particles (LDL) to sub endothelial space
(Tabas et al., 2007). Once endothelium has been activated by
risk factors, it expresses adhesion molecules such as E-selectin,
vascular cell adhesion molecule (VCAM-1) and intercellular
adhesion molecule (ICAM-1), which attracts leukocytes. They
adhere to endothelial lumen and migrate through vascular wall
to the media. There, these cells express scavenger receptors
and phagocyte oxidized LDL (oxLDL) turning into foam cells
(Stephen et al., 2010). Growth factors and cytokines released
by inflammatory cells contribute to the formation of a fibrous
cap of smooth muscle and extracellular matrix around the lipid
core, which compromises vascular lumen (Ross, 1999; Lusis,
2000; Hansson et al., 2002; Libby et al., 2010). Thus, it is
clear that any factor involved in modulation of inflammatory
response can influence atheroma development. Inflammatory
process is not only involved in progression of atherosclerosis but
is also responsible for acute thrombotic complications due to
plaque rupture (Kumada et al., 2004), which may represent the
major problematic event associated with atherosclerosis. Many
adipokines can induce angiogenesis, which has deleterious effects
on atheroma as the proliferation and migration of endothelial
cells can lead to plaque destabilization and rupture (Van de
Voorde et al., 2013). The adipokines effects on atherogenesis are
illustrated in Figure 4.
Adiponectin and Atherosclerosis
Adiponectin can influence several steps in atheroma formation,
from endothelial dysfunction to plaque rupture (Zhu et al.,
2008; Lindgren et al., 2013). Accordingly to the “response to
injury” theory of atherogenesis proposed by Ross (1999), the
first step toward atheroma formation is an injury to endothelial
wall. Considering that adiponectin can diminish endothelial
response to mechanical injury (Fisman and Tenenbaum, 2014),
it is clear that this adipokine present protective role in
atherosclerosis. Hypercholesterolemia, the main risk factor to
atheroma formation, can reduce endothelial progenitor cells
(EPC) number and function (Dussault et al., 2009). Adiponectin
was shown to recover EPC number and function, favoring
endothelial repair (Huang et al., 2011; Issan et al., 2012; Fisman
and Tenenbaum, 2014).
It has already been shown that adiponectin can inhibit
the expression of VCAM-1, ICAM-1 and E-selectin by the
endothelium (Ouchi et al., 2000), the initial phase of leukocyte
migration through arterial wall. Adiponectin can modulate
macrophage phenotype from the activated macrophage to an
anti-inflammatory phenotype (Ouchi et al., 1999; Kumada et al.,
2004), inhibiting its transformation into foam cell. Moreover,
it can also reduce intracellular cholesteryl ester content,
suppress TNFα production and stimulate the production
of IL-10, which present anti-inflammatory features (Ouchi
et al., 1999). In 2001, Ouchi and colleagues demonstrated
that adiponectin is capable of diminishing the expression
of class A scavenger receptors in macrophages, resulting in
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FIGURE 4 | The process of atherogenesis can be influenced by diverse adipokines.1: Endothelial dysfunction (ED) and transmigration of LDL particles to
subendothelial space can be worsen by leptin and TNFα. Adiponectin, which is reduced in obesity, recovers endothelial function. 2: Once in subendothelial space LDL
is oxidized (oxLDL), which is positively related to MCP-1 levels. Leptin, IL-6, MCP-1 and TNFα increase the expression of adhesion molecules in endothelium and
increase leucocyte transmigration. 3: Monocytes turn into macrophages under the stimulus of MCP-1 and phagocytes oxLDL, turning into foam cells. Adiponectin
inhibits phagocytosis of oxLDL and foam cell formation. 4: IL-6 can be produced by local smooth muscle cells (SMC) under the stimulus of angiotensin II. Along with
MCP-1, it increases recruitment and proliferation of SMC and extracellular matrix deposition to form a fibrous cap around a lipid-rich necrotic core. 5: Due to
stimulation of matrix metalloproteinases and prothrombotic molecules, MCP-1 and leptin favors plaque rupture and thrombus formation, while adiponectin inhibits
thrombosis. Periadventitial adipose tissue (PAAT) and leptin induce the production of proinflammatory adipokines. Red arrows represent proinflammatory pathways
which are stimulated during obesity and contribute to atherogenesis. Blue arrows represent anti-inflammatory pathways which are inhibited during obesity since
adiponectin levels are low. Green arrows represent production or stimulation of adipokine secretion.
inhibition of foam cell transformation. In addition, it induced
cholesterol eﬄux from macrophages due to upregulation of
ATP-binding cassette transporter (ABCA1) (Ouchi et al.,
2001; Tsubakio-Yamamoto et al., 2008). It has been shown
that adiponectin is capable to increase the expression of
tissue inhibitor of metalloproteinase 1 (TIMP1), protecting
against plaque rupture and thrombotic events (Kumada et al.,
2004).
Although adiponectin can be considered as an anti-
inflammatory adipokine, some studies have indicated that its
level is related more closely to the degree of insulin resistance
than to the degree of adiposity in humans (Weyer et al.,
2001; Ohman et al., 2008) and that the relationship between
adiponectin concentration and CVD is still controversial (Weyer
et al., 2001). One possible explanation is the different forms
of adiponectin found in plasma and their diverse biological
effects. Adiponectin can be present as a trimer, with anti-
inflammatory properties, as a trimer-dimer or as a large
multimeric structure, which present proinflammatory effect. In
this context, the percentage of the different isoforms observed
in diverse pathophysiological conditions could be responsible
for discrepant observations (Kim et al., 2012; Hao et al.,
2013). Another possible explanation is that adiponectin acts
differently depending on the receptor activated. This adipokine
can mediate its effects via AdipoR1 and AdipoR2, respectively. In
2013, Lindgren and colleagues demonstrated that crossbreeding
apolipoprotein E knockout mice (apoE−/−) and AdipoR2−/−
animals can generate a lineage which presents smaller plaque
area in brachiocephalic artery, suggesting that the activation of
this receptor has proatherogenic effect, despite no differences
in plasma lipid profile (Lindgren et al., 2013). However, it was
described that overexpression of adiponectin protects against
atherosclerosis in apoE−/− mice (Yamauchi et al., 2003b).
Some authors defend that adiponectin can be used as a
marker of cardiovascular risk, once it correlates negatively
with coronary artery disease (Ouchi et al., 1999), although
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the diverse actions of this adipokine and different responses
depending on which receptor is activated make it still a
controversial issue. Nevertheless, it is generally well accepted that
hypoadiponectinemia (<4µg/mL) is associated with a variety of
diseases, including atherosclerosis, DM, hypertension and others,
although hyperadiponectinemia can be associated with increased
renal and pulmonary diseases (Kishida et al., 2014).
TNFα and Atherosclerosis
Although it was initially suggested that the main source of TNFα
in obesity were adipocytes, it is now well recognized that M1
macrophages infiltrated in adipose tissue are responsible for
increased levels of this cytokine (Arkan et al., 2005; Solinas et al.,
2007; Galic et al., 2010; Nakamura et al., 2014). Still, TNFα was
the first adipokine suggested to represent a link between obesity,
inflammation and diabetes (Hotamisligil et al., 1993; Galic et al.,
2010).
Similarly to adiponectin, TNFα is considered to be involved
in all aspects regarding atheroma formation, although it
presents proinflammatory properties. In endothelial cells, TNFα
induces the activation of proinflammatory, procoagulant and
proliferative genes (Ohta et al., 2005; Xiao et al., 2009; Ntaios
et al., 2013; Nakamura et al., 2014; Steyers and Miller, 2014).
Considering that endothelial dysfunction can be defined as an
unbalance in the production of vasoconstrictors and vasodilators,
pro and anti-inflammatory substances, inhibitor and stimulator
factors and pro and anti-coagulators (Rubanyi, 1993), the
production of TNFα during obesity can be considered as an
inductor of endothelial dysfunction (Kobayasi et al., 2010; Steyers
and Miller, 2014). Endothelial dysfunction is the first event in
atherogenesis pathway (Ross, 1999) and the induction of this
stat by TNFα is, at least in part, responsible for the increased
incidence of atherosclerosis-related events in obese patients.
Another marker of endothelial dysfunction is the inability of
acetylcholine to induce endothelium-dependent relaxation in
vessel preparations in vitro (Balarini et al., 2013) and this was
also induced by TNFα (Wang et al., 1994) since it reduces
endothelial nitric oxide synthase (eNOS) expression and activity
(Steyers and Miller, 2014). Vasocrine signaling by TNFα derived
from periadventitial adipose tissue (PAAT) is also responsible for
decreased NO production and endothelial dysfunction (Yudkin
et al., 2005; Ronti et al., 2006).
Another aspect of atherosclerosis-related inflammation that is
induced by TNFα is the alteration in endothelial permeability.
This adipokine can increase the expression of adhesionmolecules
(ICAM-1, VCAM-1, and E-selectin) by endothelium and alter
endothelial cell morphology, augmenting its permeability not
only to immune cells but also to small particles like LDL (Marcos-
Ramiro et al., 2014; Steyers and Miller, 2014). Interestingly,
Zhang and colleagues demonstrated that TNFα is capable to
induce transcytosis of LDL at the first stages of atherosclerosis
development through a mechanism dependent of nuclear factor
kappa B (NF-κB) and peroxisome proliferator-activated receptor
gamma (PPAR-γ) crosstalk (Zhang et al., 2014). The activation of
endothelium and increasing in expression of adhesion molecules
by TNFα can be reduced by adiponectin (Van de Voorde et al.,
2013).
TNFα is first synthesized as a transmembrane protein and
then is turned into is soluble form through the cleavage by
ADAM-17 (A disintegrin A metalloproteinase 17), which
increased activity is related to ischemia, heart failure,
atherosclerosis, diabetes and hypertension (Peschon et al.,
1998; Menghini et al., 2013; Xia et al., 2013; Speck et al., 2015).
There is only one endogen inhibitor of ADAM-17, known as
tissue inhibitor of metalloproteinase 3 (TIMP3), which activity
is reduced in obesity, atherosclerosis, diabetes and insulin
resistance (Chavey et al., 2003; Cardellini et al., 2009, 2011;
Menghini et al., 2013). This results in increased ADAM17 action
and augmented TNFα.
Adipokines can also be considered important clinical
biomarkers and pharmacologic targets to treat atherosclerosis.
Blood level of TNFα was associated with coronary heart disease
in elderly, serving as a biomarker for CVD risk (Cesari et al.,
2003). The inhibition of TNFα-induced signaling pathways that
lead to LDL transcytosis was efficient in reducing atherosclerosis
in experimental model (Zhang et al., 2014) as well as silencing
of TNFα-encoding gene (Brånén et al., 2004). Apart from
decreasing plasma cholesterol, simvastatin reduced leptin, and
TNFα, increased adiponectin levels and decreased TNFα-
induced apoptosis of endothelial progenitor cells (EPC), which
contributes to clinical effectiveness of this class of drugs (Du
et al., 2014; Krysiak et al., 2014). This highlights that strategies
aimed to modulate inflammatory actions elicited by TNFα could
be promising therapeutic options to treat atherosclerosis.
IL-6 and Atherosclerosis
Interleukin 6 (IL-6) is an important adipokin secreted by
adipocytes. However, it can also be released by smooth muscle
cells under the influence of angiotensin II (Libby, 2002). Tikellis
and colleagues demonstrated that feeding apoE−/− mouse with a
low salt diet activated the renin-angiotensin-aldosterone system
(RAAS) and increased IL-6 in serum and aorta (Tikellis et al.,
2012). As previously discussed, IL-6 can present different effects
depending on the signaling pathway activated (classic or trans-
signaling), the duration of the stimulus and the source of the
cytokine (Schuett et al., 2009; Piya et al., 2013). It seems that
pro- and anti-inflammatory effects of IL-6 depends on ADAM17
activation and the balance between the activation of classic and
trans-signaling cascades (Scheller et al., 2011). Considering that
in atherosclerosis ADAM17 is overactive (Speck et al., 2015), IL-6
is expected to present a proinflammatory role in this disease.
In endothelial cells, IL-6 trans-signaling is responsible for the
up regulation of adhesion molecules such as ICAM-1, VCAM-
1 and E-selectin and the control of lymphocytes trafficking
(Chen et al., 2006; Scheller et al., 2011), which in turn favors
an proatherogenic phenotype. Also, this adipokine contributes
to the differentiation of monocytes into macrophages (Chomarat
et al., 2000). Interestingly, Speck and colleagues observed
that the antiatherogenic effect of fish oil is due to reduction
in ADAM17 activity. The consequent decreased release of
endothelial adhesion molecules would contribute to endothelial
barrier improvement. Moreover, authors found a reduction in
sIL-6R in animals that received fish oil (Speck et al., 2015),
which reinforces the role played by IL-6 trans-signaling in
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early stages of atherosclerosis development. Additionally, IL-
6 is negatively correlated with EPC number in patients with
rheumatoid arthritis. These patients present increased morbidity
and mortality attributable to accelerated atherosclerosis and
develop endothelial dysfunction and EPC impaired function even
at young age (Herbrig et al., 2006). IL-6 can also influence the
production of other cytokines. It was reported that the increase
in C-reactive protein (CRP), a marker of acute inflammation, is
rather produced by the liver under the influence of IL-6 than a
direct product of adipose cells (Bays, 2009). It was described that
IL-6 can stimulate the production of matrix metalloproteinases,
which contribute to plaque vulnerability/rupture and arterial
remodeling (Watanabe and Ikeda, 2004; Schuett et al., 2009).
Blocking IL-6 effects using neutralizing monoclonal
antibodies to treat atherosclerosis is controversial. In
patients with lymphoproliferative disorder it was associated
with an increase in body weight, hypertriglyceridemia and
hypercholesterolemia (Nishimoto et al., 2005), which could favor
the development of atherosclerotic plaques. Although inhibition
of IL-6 with tocilizumab (an antibody that binds to both soluble
and membrane bound IL-6R) has been reported to improve
endothelial function and reduce arterial stiffness (Protogerou
et al., 2011), it also increases LDL-cholesterol (Ridker and
Lüscher, 2014). Thus, anti-IL-6 therapies are still considered
a double-edged sword in atherosclerosis management. On the
other hand, indirect approaches can reduce inflammatory actions
of IL-6. Statin therapy was reported to reduce the IL-6-induced
production of CRP and MCP-1, important inflammatory
markers (Rodriguez et al., 2012). Blocking renin-angiotensin
system (RAAS) with an inhibitor of angiotensin converting
enzyme (ACE) reduced IL-6 and inflammation markers in
atherosclerosis experimental model (Tikellis et al., 2012).
MCP-1 and Atherosclerosis
The release of MCP-1 by endothelial cells, smooth muscle cells,
T cells, monocytes, macrophages and foam cells perpetuates
inflammation and lipid accumulation in atheroma (Tabata et al.,
2003; Lin et al., 2014), although experimentally this depends on
a high cholesterol diet (Namiki et al., 2002). Also, adipocyte-
derived MCP-1 is overexpressed in obesity, in proportion of
adiposity (Weisberg et al., 2006). In early atheroma formation,
MCP-1 can be considered the link between oxLDL and foam cell
recruitment to vessel wall whereas oxLDL (but not native LDL)
induce MCP-1 production (Cushing et al., 1990). Apart from
migration of monocytes/macrophages, MCP-1 also controls its
differentiation into foam cells. During this process, the number of
LDL receptors decrease while the number of scavenger receptors
(responsible for phagocytosis of oxLDL) increases (Stephen et al.,
2010). It was reported that MCP-1 induce the expression of
scavenger receptors on monocytes through extracellular signal-
regulated kinase (ERK) (Tabata et al., 2003). In summary,
MCP-1 can be considered a key molecule in the regulation of
oxLDL phagocytosis/foam cell formation sequence. Interestingly,
Hashizume and Mihara showed that oxLDL-induced MCP-1 was
augmented by IL-6 and TNFα and that this mechanism is also
involved in the induction of scavenger receptors by IL-6 and
TNFα, which creates a self-perpetuating and amplifying cycle
of inflammation and atherogenesis and suggests that IL-6 and
TNFα participate in atherogenesis process also via oxLDL/MCP-
1 induction (Hashizume and Mihara, 2012; Uchida et al., 2012).
During fibrous cap formation around the lipid core, MCP-1
participates in smooth muscle cells (SMC) proliferation and
activation (Gonzalez-Quesada and Frangogiannis, 2009).
MCP-1 is involved not only in the initial phase of
atherosclerosis development but also in the final fatal
complication of atherosclerotic plaque rupture and thrombosis.
In endothelial cells, MCP-1 can induce the secretion of matrix
metalloproteinases (Werle et al., 2002; Gonzalez-Quesada and
Frangogiannis, 2009), which is crucial for plaque disruption. In
addition, it was described that MCP-1 contributes to thrombin
generation, thrombus formation and upregulation of tissue
factor and plasminogen activation inhibitor-1 (PAI-1) (Charo
and Taubman, 2004; Gonzalez-Quesada and Frangogiannis,
2009; Uchida et al., 2012).
Gonzalez-Quesada and Frangogiannis state that the effects of
MCP-1 inhibition after myocardial infarction should be carefully
evaluated because the suppression of this adipokine could delay
the phagocytosis of dead cardiomyocytes and extend the injury
extension (Gonzalez-Quesada and Frangogiannis, 2009). In this
context, similarly to IL-6, indirect approaches that decrease
not only MCP-1 but also other inflammatory markers are
of interest. Statins were shown to decrease MCP-1, IL-6, IL-
8 in hypercholesterolemic patients (Rezaie-Majd et al., 2002),
although this might be dependent on treatment duration since
that high doses of atorvastatin during 5 days did not modified
inflammatory markers, including MCP-1, in aorta of high fat-
feeding apoE−/− mice (Ekstrand et al., 2015). Nevertheless,
MCP-1 inhibition resulted in decreased TNFα, IL-6, tissue factor
and PAI-1 in an inflammation model induced by stress in mice
(Uchida et al., 2012), suggesting a beneficial effect not only in
inflammation but also in the prothrombotic state in the presence
of atherosclerosis.
Leptin and Atherosclerosis
Unlike other adipokines, which are produced from different
sources, leptin is mainly produced by adipocytes and plasma
levels are positively correlated with white adipose tissue
mass (Scotece et al., 2012). It regulates energy balance and
metabolism both centrally and peripherally (Koh et al., 2012).
In cardiovascular system, blood vessels and cardiomyocytes
express the specific leptin receptor (named Ob-R, which presents
6 isoforms) and its actions are potentially proatherogenic,
prothrombotic and angiogenic (Koh et al., 2012; Scotece et al.,
2012; Adya et al., 2015). Interestingly, in obese individuals only
the anorectic effect of leptin is impaired, whereas other effects are
maintained (a phenomenon known as selective leptin resistance)
(Mark et al., 2002; Singh et al., 2010; Adya et al., 2015) thus
hyperleptinemia contributes to atherogenesis in these patients.
Hyperleptinemia is associated to impairment of NO-
dependent vasorelaxation, increase in oxidative stress as well
as increase in endothelin (a potent vasoconstrictor) (Yamagishi
et al., 2001; Adya et al., 2015; Husain, 2015). All these features
are markers of endothelial dysfunction, the first step in
atherogenesis. It was described that leptin increases NADPH
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oxidase expression and activity (Dong et al., 2006; Schroeter et al.,
2012). Moreover, it increases the expression of type-1 angiotensin
II receptor (AT1R) in smooth muscle cells (Zeidan et al., 2005).
It is well established that angiotensin II increases oxidative stress
through AT1R-dependent activation of NADPH oxidase (Braga
et al., 2011). Thus, leptin potentiates deleterious angiotensin II
effects in vascular function, which is potentially dangerous in
hypertensive obese patients. Conversely, angiotensin II increases
leptin synthesis (Koh et al., 2012), generating a self-perpetuating
cycle of excessive oxidative stress and vascular dysfunction.
In initial phase of atheroma formation, leptin plays a crucial
role in inflammatory pathways. It increases the secretion of
TNFα, IL-6, and MCP-1 (Yamagishi et al., 2001; Koh et al., 2012)
important inflammatory molecules as previously discussed. The
expression of adhesionmolecules such as VCAM-1, ICAM-1, and
E-selectin are also increased by leptin (Adya et al., 2015). This
favors monocytes attraction and migration through endothelial
wall. During atheroma formation, leptin is also involved growth
and migration of SMC (Zeidan et al., 2005; Husain, 2015).
Leptin also induces a prothrombotic state once it enhances
platelets activation and aggregation, thrombus formation and
PAI-1 expression (Beltowski, 2006; Singh et al., 2010; Husain,
2015). Plaque rupture is an important event that usually precedes
thrombus formation and leptin is involved in plaque rupture
since it induces the production of MMP (Li et al., 2005; Adya
et al., 2015).
Hyperleptinemia is related to acute cardiovascular events
independent of traditional risk factors (Koh et al., 2012). Leptin
treatment was described to be efficient in reducing weight in
leptin-deficient obese mice and humans, but this effect was
small in diet-induced obesity (Blüher, 2014), probably due to
the selective leptin resistance previously mentioned. Although
leptin may be involved in inflammation response in certainly
conditions, inhibition of inflammatory cytokines such as TNFα
did not modified leptin levels (Scotece et al., 2012). On the
other hand, considering the synergism between angiotensin II
and leptin, antihypertensive therapies may decrease leptin levels.
Umeda and colleagues demonstrated that inhibition of AT1R
decreased leptin in adipose tissue (Umeda et al., 2003). Also,
inhibition of angiotensin II synthesis decreased leptin (Cassis
et al., 2004). These results highlight the importance of blood
pressure control in obese hypertensive patients, especially using
RAAS-antagonists.
Periadventitial Adipose Tissue
Considering that patients with autoimmune diseases have
increased risk for atherosclerosis, inflammation in different
sites can be involved in atherogenesis, possibly due to the
generation of cytokines and other factors that can be released
into the circulation (Hahn et al., 2007; Rosenfeld, 2013). Medium
and large arteries, where atherosclerotic plaques develop, are
surrounded by periadventitial adipose tissue (PAAT), which
provides chemical messengers and vasoactive mediators into
the bloodstream and function as a paracrine organ (Mattu and
Randeva, 2013; Chaldakov et al., 2014). Even though the view
of atherosclerosis has been mainly focused on intimal lesions
and luminal loss, it is likely that other components of vascular
wall are involved in this inflammatory process (Chaldakov et al.,
2014). In this regard, inflamed PAAT can be considered as
an important source of pro and anti-inflammatory adipokines
which contribute to plaque formation and stabilization. In
the heart, adventitial lymphocytic inflammation is related to
epicardial fat metabolism. It was observed that, in epicardial
fat harvest during coronary bypass, there was an increase in
proinflammatory markers (as IL-6, MCP-1, and TNFα) when
compared to abdominal fat (Mazurek et al., 2003; Tavora
et al., 2010). This confirms the relation between PAAT and
atherosclerosis. Moreover, inflamed fat from other sources can
also be responsible, at least in part, for atherogenesis. It was
already shown that that inflammatory visceral fat accelerated
atherosclerosis in apoE−/−, possibly due to increase in MCP-1
since a pharmacological approach capable of reducing MCP-1
was efficient in reducing atherosclerosis in this model (Ohman
et al., 2008).
CONCLUSION
In summary, it is now well established that adipose tissue
can be considered a source of diverse molecules, which play
important roles in the body homeostasis. Obese adipose tissue
can induce a state of low-grade inflammation due to secretion
of proinflammatory adipokines and the reduced secretion of
anti-inflammatory ones. In this brief review we highlighted
the participation of the main adipokines in insulin resistance,
diabetes and atherosclerosis. The comprehension of molecular
pathways involved in the mechanism of action of these molecules
created the possibility for clinical and translational studies
aiming to provide new therapeutic interventions. Patients who
suffer from chronic inflammatory diseases present increased
risk of diabetes and atherosclerosis. However, the use of
anti-inflammatory therapies to treat these conditions is still
controversial and often the results are inferior to the expected.
On the other hand, indirect approaches which culminate
in reduction of adipokines secretion or signaling seems to
be promising. Nevertheless, considering that obesity is a
manipulable risk factor which is often related to individual life
style, an important approach to prevent CVD and diabetes is still
the alteration of bad alimentary habits and reduction in body
weight.
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